Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2022 Filed Sep 6, 2022 17:50 UTC |
Dahowski DianeEVP, Global Supply Chain
|
GrantRestricted Stock Units · Derivative | 2,082 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019189 · form4.xml · derivative · entry 3 Dahowski Diane · CIK 0001926636 · EVP, Global Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,082 Underlying: Bio-Rad A Common Stock · 2,082 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F4 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 17:50 UTC |
Dahowski DianeEVP, Global Supply Chain
|
Tax withholdingBio-Rad A Common Stock | 114 | $486.25 | $55,432.50 |
DisclosureSEC source: 0001062993-22-019189 · form4.xml · nonDerivative · entry 2 Dahowski Diane · CIK 0001926636 · EVP, Global Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,237.3347 Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 17:50 UTC |
Dahowski DianeEVP, Global Supply Chain
|
Exercise / conversionBio-Rad A Common Stock | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019189 · form4.xml · nonDerivative · entry 1 Dahowski Diane · CIK 0001926636 · EVP, Global Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,351.3347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. F2 · balance_after: Includes 14.3707 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2022 Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 17:46 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
Exercise / conversionRestricted Stock Units · Derivative | 405 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019187 · form4.xml · derivative · entry 4 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,216 Underlying: Bio-Rad A Common Stock · 405 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On September 1, 2021, the reporting person was granted 1,621 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On September 1, 2021, the reporting person was granted 1,621 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 17:46 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
GrantRestricted Stock Units · Derivative | 2,082 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019187 · form4.xml · derivative · entry 3 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,082 Underlying: Bio-Rad A Common Stock · 2,082 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 17:46 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
Tax withholdingBio-Rad A Common Stock | 141 | $486.25 | $68,561.25 |
DisclosureSEC source: 0001062993-22-019187 · form4.xml · nonDerivative · entry 2 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,337 Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 17:46 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
Exercise / conversionBio-Rad A Common Stock | 405 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019187 · form4.xml · nonDerivative · entry 1 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 17:22 UTC |
Daskal IlanEVP, Chief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 455 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019183 · form4.xml · derivative · entry 4 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 Underlying: Bio-Rad A Common Stock · 455 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On September 1, 2021, the reporting person was granted 1,823 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On September 1, 2021, the reporting person was granted 1,823 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 17:22 UTC |
Daskal IlanEVP, Chief Financial Officer
|
GrantRestricted Stock Units · Derivative | 2,776 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019183 · form4.xml · derivative · entry 3 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,776 Underlying: Bio-Rad A Common Stock · 2,776 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 17:22 UTC |
Daskal IlanEVP, Chief Financial Officer
|
Tax withholdingBio-Rad A Common Stock | 226 | $486.25 | $109,892.50 |
DisclosureSEC source: 0001062993-22-019183 · form4.xml · nonDerivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 681 Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 17:22 UTC |
Daskal IlanEVP, Chief Financial Officer
|
Exercise / conversionBio-Rad A Common Stock | 455 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019183 · form4.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| August 26, 2022 Filed Aug 29, 2022 23:45 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 39,250 | $0.00 Strike: $107.32 | $0.00 |
DisclosureSEC source: 0001062993-22-018842 · form4.xml · derivative · entry 6 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad B Common Stock · 39,250 shares Expires 2022-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing a right to purchase a total of 39,250 shares, became exercisable in five equal annual installments beginning on September 12, 2013, which was the first anniversary of the date on which the option was granted. Read SEC document |
| August 26, 2022 Filed Aug 29, 2022 23:45 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Tax withholdingBio-Rad B Common Stock | 23,749 | $495.28 | $11,762,404.72 |
DisclosureSEC source: 0001062993-22-018842 · form4.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,647 Read SEC document |
| August 26, 2022 Filed Aug 29, 2022 23:45 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionBio-Rad B Common Stock | 39,250 | $107.32 | $4,212,310.00 |
DisclosureSEC source: 0001062993-22-018842 · form4.xml · nonDerivative · entry 1 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 20:25 UTC |
RAMALINGAM AJITSVP, Chief Accounting Officer
|
SaleBio-Rad A Common Stock | 518 | $537.00 | $278,166.00 |
DisclosureSEC source: 0001062993-22-017487 · form4.xml · nonDerivative · entry 1 RAMALINGAM AJIT · CIK 0001807891 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98.4969 F1 · balance_after: Includes 14.8086 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2022. Read SEC document |
| April 29, 2022 Filed May 2, 2022 18:44 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-011169 · form4.xml · derivative · entry 3 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Bio-Rad A Common Stock · 1,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On April 29, 2019, the reporting person was granted 5,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On April 29, 2019, the reporting person was granted 5,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| April 29, 2022 Filed May 2, 2022 18:44 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
Tax withholdingBio-Rad A Common Stock | 471 | $512.06 | $241,180.26 |
DisclosureSEC source: 0001062993-22-011169 · form4.xml · nonDerivative · entry 2 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,293.1217 Read SEC document |
| April 29, 2022 Filed May 2, 2022 18:44 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
Exercise / conversionBio-Rad A Common Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-011169 · form4.xml · nonDerivative · entry 1 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,764.1217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. F2 · balance_after: Includes 13.3620 and 14.8416 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 09/30/2021 and 03/31/2022, respectively. Read SEC document |
| April 29, 2022 Filed May 2, 2022 18:42 UTC |
RAMALINGAM AJITSVP, Chief Accounting Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 277 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-011167 · form4.xml · derivative · entry 3 RAMALINGAM AJIT · CIK 0001807891 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 831 Underlying: Bio-Rad A Common Stock · 277 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On April 29, 2020, the reporting person was granted 1,384 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On April 29, 2020, the reporting person was granted 1,384 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| April 29, 2022 Filed May 2, 2022 18:42 UTC |
RAMALINGAM AJITSVP, Chief Accounting Officer
|
Tax withholdingBio-Rad A Common Stock | 96 | $512.06 | $49,157.76 |
DisclosureSEC source: 0001062993-22-011167 · form4.xml · nonDerivative · entry 2 RAMALINGAM AJIT · CIK 0001807891 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601.6883 Read SEC document |
| April 29, 2022 Filed May 2, 2022 18:42 UTC |
RAMALINGAM AJITSVP, Chief Accounting Officer
|
Exercise / conversionBio-Rad A Common Stock | 277 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-011167 · form4.xml · nonDerivative · entry 1 RAMALINGAM AJIT · CIK 0001807891 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 697.6883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. F2 · balance_after: Includes 12.1142, 5.1601, and 13.0147 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 09/30/2021, 12/31/2021, and 03/31/2022, respectively. Read SEC document |
| April 08, 2022 Filed Apr 11, 2022 16:16 UTC |
Daskal IlanEVP, Chief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 700 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-010014 · form4.xml · derivative · entry 3 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Bio-Rad A Common Stock · 700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: On April 8, 2019, the reporting person was granted 3,500 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On April 8, 2019, the reporting person was granted 3,500 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| April 08, 2022 Filed Apr 11, 2022 16:16 UTC |
Daskal IlanEVP, Chief Financial Officer
|
Tax withholdingBio-Rad A Common Stock | 257 | $597.16 | $153,470.12 |
DisclosureSEC source: 0001062993-22-010014 · form4.xml · nonDerivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452 Read SEC document |
| April 08, 2022 Filed Apr 11, 2022 16:16 UTC |
Daskal IlanEVP, Chief Financial Officer
|
Exercise / conversionBio-Rad A Common Stock | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-010014 · form4.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 19:21 UTC |
WRIGHT DARAExecutive Vice President
|
Exercise / conversionRestricted Stock Units · Derivative | 502 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-013122 · form4.xml · derivative · entry 3 WRIGHT DARA · CIK 0001796980 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,507 Underlying: Bio-Rad A Common Stock · 502 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: On December 16, 2019, the reporting person was granted 2,511 restricted stock units, vesting in 5 equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On December 16, 2019, the reporting person was granted 2,511 restricted stock units, vesting in 5 equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 19:21 UTC |
WRIGHT DARAExecutive Vice President
|
Tax withholdingBio-Rad A Common Stock | 221 | $734.34 | $162,289.14 |
DisclosureSEC source: 0001062993-21-013122 · form4.xml · nonDerivative · entry 2 WRIGHT DARA · CIK 0001796980 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 892 Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 19:21 UTC |
WRIGHT DARAExecutive Vice President
|
Exercise / conversionBio-Rad A Common Stock | 502 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-013122 · form4.xml · nonDerivative · entry 1 WRIGHT DARA · CIK 0001796980 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,113 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 15:55 UTC |
TUMOLO ANNETTEExecutive Vice President
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 600 | $0.00 Strike: $159.32 | $0.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · derivative · entry 15 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 600 shares Expires 2026-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 7, 2017, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 15:55 UTC |
TUMOLO ANNETTEExecutive Vice President
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,400 | $0.00 Strike: $215.98 | $0.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · derivative · entry 14 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Bio-Rad A Common Stock · 2,400 shares Expires 2027-09-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 5, 2018, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 15:55 UTC |
TUMOLO ANNETTEExecutive Vice President
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,800 | $0.00 Strike: $326.15 | $0.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · derivative · entry 13 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Underlying: Bio-Rad A Common Stock · 1,800 shares Expires 2028-09-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 4, 2019, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 15:55 UTC |
TUMOLO ANNETTEExecutive Vice President
|
SaleBio-Rad A Common Stock | 4,800 | $750.05 | $3,600,240.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · nonDerivative · entry 10 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,593.3476 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $750.00 to $750.61, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 15:55 UTC |
TUMOLO ANNETTEExecutive Vice President
|
Exercise / conversionBio-Rad A Common Stock | 1,800 | $326.15 | $587,070.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · nonDerivative · entry 9 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,393.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 15:55 UTC |
TUMOLO ANNETTEExecutive Vice President
|
Exercise / conversionBio-Rad A Common Stock | 2,400 | $215.98 | $518,352.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · nonDerivative · entry 8 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,593.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 15:55 UTC |
TUMOLO ANNETTEExecutive Vice President
|
Exercise / conversionBio-Rad A Common Stock | 600 | $159.32 | $95,592.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · nonDerivative · entry 7 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,193.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 15:55 UTC |
TUMOLO ANNETTEExecutive Vice President
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,113 | $0.00 Strike: $333.34 | $0.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · derivative · entry 12 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,671 Underlying: Bio-Rad A Common Stock · 1,113 shares Expires 2029-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing a right to purchase a total of 2,784 shares, became exercisable in five equal annual installments beginning on September 3, 2020, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 15:55 UTC |
TUMOLO ANNETTEExecutive Vice President
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 433 | $0.00 Strike: $524.30 | $0.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · derivative · entry 11 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 Underlying: Bio-Rad A Common Stock · 433 shares Expires 2030-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing a right to purchase a total of 1,733 shares, became exercisable in four equal annual installments beginning on September 2, 2021, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 15:55 UTC |
TUMOLO ANNETTEExecutive Vice President
|
SaleBio-Rad A Common Stock | 500 | $750.00 | $375,000.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · nonDerivative · entry 6 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,593.3476 Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 15:55 UTC |
TUMOLO ANNETTEExecutive Vice President
|
SaleBio-Rad A Common Stock | 613 | $748.84 | $459,038.92 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · nonDerivative · entry 5 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,093.3476 Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 15:55 UTC |
TUMOLO ANNETTEExecutive Vice President
|
SaleBio-Rad A Common Stock | 433 | $748.08 | $323,918.64 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · nonDerivative · entry 4 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,706.3476 Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 15:55 UTC |
TUMOLO ANNETTEExecutive Vice President
|
Exercise / conversionBio-Rad A Common Stock | 433 | $524.30 | $227,021.90 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · nonDerivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,139.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 15:55 UTC |
TUMOLO ANNETTEExecutive Vice President
|
Exercise / conversionBio-Rad A Common Stock | 500 | $333.34 | $166,670.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · nonDerivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,706.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 15:55 UTC |
TUMOLO ANNETTEExecutive Vice President
|
Exercise / conversionBio-Rad A Common Stock | 613 | $333.34 | $204,337.42 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,206.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2021 Filed Nov 23, 2021 19:30 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
GiftBio-Rad B Common Stock | 20 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-011448 · form4.xml · nonDerivative · entry 3 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,858 F1 · ownership.nature: The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| November 09, 2021 Filed Nov 23, 2021 19:30 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
GiftBio-Rad B Common Stock | 20 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-011448 · form4.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,146 Read SEC document |
| November 09, 2021 Filed Nov 23, 2021 19:29 UTC |
SCHWARTZ ALICE NDirector · 10% owner
|
GiftBio-Rad B Common Stock | 120 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-011446 · form4.xml · nonDerivative · entry 6 SCHWARTZ ALICE N · CIK 0001248076 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Alice N. Schwartz Revocable Trust Disclosed balance after: 438,398 Read SEC document |
| November 09, 2021 Filed Nov 23, 2021 19:29 UTC |
SCHWARTZ ALICE NDirector · 10% owner
|
GiftBio-Rad A Common Stock | 1,366 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-011446 · form4.xml · nonDerivative · entry 1 SCHWARTZ ALICE N · CIK 0001248076 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Alice N. Schwartz Revocable Trust Disclosed balance after: 1,790,455 Read SEC document |
| November 09, 2021 Filed Nov 23, 2021 19:28 UTC |
SCHWARTZ STEVEN D10% owner
|
GiftBio-Rad B Common Stock | 20 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-011444 · form4.xml · nonDerivative · entry 4 SCHWARTZ STEVEN D · CIK 0000940804 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,858 F1 · ownership.nature: The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| November 09, 2021 Filed Nov 23, 2021 19:28 UTC |
SCHWARTZ STEVEN D10% owner
|
GiftBio-Rad B Common Stock | 20 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-011444 · form4.xml · nonDerivative · entry 3 SCHWARTZ STEVEN D · CIK 0000940804 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,086 Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 13:39 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 37,000 | $0.00 Strike: $100.06 | $0.00 |
DisclosureSEC source: 0001062993-21-008418 · form4.xml · derivative · entry 9 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad B Common Stock · 37,000 shares Expires 2021-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing a right to purchase a total of 37,000 shares, became exercisable in five equal annual installments beginning on November 4, 2012, which was the first anniversary of the date on which the option was granted. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 13:39 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionRestricted Stock Units · Derivative | 3,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008418 · form4.xml · derivative · entry 8 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad B Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class B common stock. F5 · derivative.exercise_date: On September 7, 2016, the reporting person was granted 15,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 7, 2016, the reporting person was granted 15,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.